By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Two investment firms today separately raised estimates for Complete Genomics and Danaher.

Oppenheimer raised its share price target for Complete Genomics to $18.50, while Jefferies increased its 2011 EPS for Danaher to $2.70 and upped its share price target for the firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.